Assessing the in vivo efficacy of doxorubicin loaded hyaluronan nanoparticles.

Magnetic nanoparticles are attractive platforms for biomedical applications including diagnosis and treatment of diseases. We have shown previously that hyaluronan-coated superparamagnetic iron oxide nanoparticles (HA-SPIONs) enhanced the efficacy of the conjugated anticancer drug doxorubicin (DOX) in vitro against drug-sensitive and drug-resistant human ovarian cancer cells. In this manuscript, we report our findings on the efficacy of DOX loaded HA-SPIONs in vivo using subcutaneous and intraperitoneal SKOV-3 ovarian tumor models in nude mice. The accumulation of the nanoparticles in subcutaneous tumors following an intravenous nanoparticle administration was confirmed by magnetic resonance imaging, and its distribution in the tumors was evaluated by confocal microscopy and Prussian blue staining. DOX delivered by nanoparticles accumulated at much higher levels and distributed wider in the tumor tissue than intravenously injected free DOX, leading to significant reduction of tumor growth. The IVIS Spectrum for in vivo bioluminescence imaging was used to aid in therapy assessment of the DOX-loaded nanoparticles on intraperitoneal ovarian tumors formed by firefly luciferase expressing human ovarian SKOV-3 cells. DOX-loaded HA-SPIONs significantly reduced tumor growth, delayed tumor development, and extended the survival of mice. Thus, utilizing HA-SPIONs as drug delivery vehicles constitutes a promising approach to tackle CD44 expressing ovarian cancer.

[1]  E. Puré,et al.  Development of drug loaded nanoparticles for tumor targeting. Part 2: Enhancement of tumor penetration through receptor mediated transcytosis in 3D tumor models. , 2013, Nanoscale.

[2]  Yaping Li,et al.  Overcoming multidrug resistance (MDR) in cancer by nanotechnology , 2010 .

[3]  A. V. D. Van Der Zee,et al.  Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer. , 2012, Critical reviews in oncology/hematology.

[4]  M. Gore,et al.  Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. , 1990, Gynecologic oncology.

[5]  Timothy A. Yap,et al.  Beyond chemotherapy: targeted therapies in ovarian cancer , 2009, Nature Reviews Cancer.

[6]  S. Pignata,et al.  Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Agarwal,et al.  Ovarian cancer: strategies for overcoming resistance to chemotherapy , 2003, Nature Reviews Cancer.

[8]  F. Szoka,et al.  A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas , 2006, Proceedings of the National Academy of Sciences.

[9]  F. Gao,et al.  The reversal effect of magnetic Fe3O4 nanoparticles loaded with cisplatin on SKOV3/DDP ovarian carcinoma cells , 2009, International journal of nanomedicine.

[10]  David C. Zhu,et al.  Hyaluronic acid immobilized magnetic nanoparticles for active targeting and imaging of macrophages. , 2010, Bioconjugate chemistry.

[11]  F. Gao,et al.  Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice , 2009, International journal of nanomedicine.

[12]  B. Goff,et al.  Ovarian carcinoma diagnosis , 2000, Cancer.

[13]  David C. Zhu,et al.  CD44 Targeting Magnetic Glyconanoparticles for Atherosclerotic Plaque Imaging , 2013, Pharmaceutical Research.

[14]  F. Gao,et al.  Reversal in multidrug resistance by magnetic nanoparticle of Fe3O4 loaded with adriamycin and tetrandrine in K562/A02 leukemic cells , 2008, International journal of nanomedicine.

[15]  P. Neven,et al.  Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view. , 2008, The oncologist.

[16]  Robert C. Bast,et al.  The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.

[17]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[18]  Robert S Mannel,et al.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  David C. Zhu,et al.  Glyconanoparticle aided detection of β-amyloid by magnetic resonance imaging and attenuation of β-amyloid induced cytotoxicity. , 2013, ACS chemical neuroscience.

[20]  J. Huober,et al.  Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). , 2007, Gynecologic oncology.

[21]  Taeghwan Hyeon,et al.  Designed synthesis of uniformly sized iron oxide nanoparticles for efficient magnetic resonance imaging contrast agents. , 2012, Chemical Society reviews.

[22]  B. Monk,et al.  Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  M. Gore,et al.  Intraperitoneal chemotherapy in ovarian cancer remains experimental. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  B. Hennessy,et al.  Molecular Targeted Therapy in Ovarian Cancer , 2011, Drugs.

[25]  R. Mumper,et al.  Anthracycline Nano-Delivery Systems to Overcome Multiple Drug Resistance: A Comprehensive Review. , 2013, Nano today.

[26]  Michael F. Flessner,et al.  Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence , 2010, Nature Reviews Clinical Oncology.

[27]  David C. Zhu,et al.  A simple method for the synthesis of hyaluronic acid coated magnetic nanoparticles for highly efficient cell labelling and in vivo imaging. , 2011, RSC advances.

[28]  Lothar Lilge,et al.  The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors , 2005, Clinical Cancer Research.

[29]  M. Piccart-Gebhart,et al.  New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. , 2008, Critical reviews in oncology/hematology.

[30]  Xing-jie Liang,et al.  Biomedical nanomaterials for imaging-guided cancer therapy. , 2012, Nanoscale.

[31]  David C. Zhu,et al.  Synthesis of β-cyclodextrin conjugated superparamagnetic iron oxide nanoparticles for selective binding and detection of cholesterol crystals. , 2012, Chemical communications.

[32]  A. Oza,et al.  Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium , 2010, International Journal of Gynecologic Cancer.

[33]  D. Chi,et al.  Epithelial Ovarian Cancer: Focus on Targeted Therapy , 2011, Journal of oncology.

[34]  David C. Zhu,et al.  Development of multifunctional hyaluronan-coated nanoparticles for imaging and drug delivery to cancer cells. , 2012, Biomacromolecules.

[35]  Anna Moore,et al.  Magnetic Nanoparticles for Cancer Diagnosis and Therapy , 2012, Pharmaceutical Research.

[36]  E. Puré,et al.  Development of drug loaded nanoparticles for tumor targeting. Part 1: Synthesis, characterization, and biological evaluation in 2D cell cultures. , 2013, Nanoscale.

[37]  R. Mohan,et al.  Nanoparticles in the treatment and diagnosis of neurological disorders: untamed dragon with fire power to heal. , 2012, Nanomedicine : nanotechnology, biology, and medicine.

[38]  H. Imhof,et al.  Superparamagnetic particles as oral contrast medium in magnetic resonance imaging of patients with treated ovarian cancer--comparison with plain MRI. , 1993, The British journal of radiology.

[39]  K. Ulbrich,et al.  The pharmacokinetics of polymer-bound adriamycin. , 1990, Biochemical pharmacology.

[40]  M. Ferrari Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[41]  M. Markman Strategies to examine new compounds for intraperitoneal use in ovarian cancer , 2008, International Journal of Gynecologic Cancer.

[42]  F. Gao,et al.  Reversal of multidrug resistance by cisplatin-loaded magnetic Fe3O4 nanoparticles in A549/DDP lung cancer cells in vitro and in vivo , 2013, International journal of nanomedicine.

[43]  David C. Zhu,et al.  Magnetic glyco-nanoparticles: a tool to detect, differentiate, and unlock the glyco-codes of cancer via magnetic resonance imaging. , 2010, Journal of the American Chemical Society.

[44]  H. Pinedo,et al.  Doxorubicin compared with related compounds in a nude mouse model for human ovarian cancer. , 1990, European journal of cancer.

[45]  Cyndee Gruden,et al.  Magnetic glyco-nanoparticles: a unique tool for rapid pathogen detection, decontamination, and strain differentiation. , 2007, Journal of the American Chemical Society.

[46]  Taeghwan Hyeon,et al.  Inorganic Nanoparticles for MRI Contrast Agents , 2009 .

[47]  Monya Baker,et al.  Nanotechnology imaging probes: smaller and more stable , 2010, Nature Methods.

[48]  M. Gore,et al.  The future of targeted therapies in ovarian cancer. , 2009, The oncologist.